Related Experiment Video
Updated: Jun 29, 2025
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
In-vitro assays for immuno-oncology drug efficacy assessment and screening for personalized cancer therapy: scopes
Md Marufur Rahman1,2, Greg Wells1, Juha K Rantala1,3
1Sheffield Ex vivo Group, Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK.
Introduction:
Immunotherapies have revolutionized cancer treatment, but often fail to produce desirable therapeutic outcomes in all patients. Due to the inter-patient heterogeneity and complexity of the tumor microenvironment, personalized treatment approaches are gaining demand. Researchers have long been using a range of in-vitro assays including 2D models, organoid co-cultures, and cancer-on-a-chip platforms for cancer drug screening. A comparative analysis of these assays with their suitability, high-throughput capacity, and clinical translatability is required for optimal translational use.
Areas Covered:
The review summarized in-vitro platforms with their comparative advantages and limitations including construction strategies, and translational potential for immuno-oncology drug efficacy assessment. We also discussed end-point analysis strategies so that researchers can contextualize their usefulness and optimally design experiments for personalized immunotherapy efficacy prediction.
Expert Opinion:
Researchers developed several in-vitro platforms that can provide information on personalized immunotherapy efficacy from different angles. Image-based assays are undoubtedly more suitable to gather a wide range of information including cellular morphology and phenotypical behaviors but need significant improvement to overcome issues including background noise, sample preparation difficulty, and long duration of experiment. More studies and clinical trials are needed to resolve these issues and validate the assays before they can be used in real-life scenarios.
Insights
Personalized cancer immunotherapy requires effective in-vitro assays for drug screening. This review compares platforms like organoids and cancer-on-a-chip, highlighting their potential for predicting treatment efficacy.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Immunotherapy has transformed cancer treatment but shows variable patient responses.
- Tumor microenvironment complexity and patient heterogeneity necessitate personalized approaches.
- In-vitro assays are crucial for assessing cancer drug efficacy and predicting treatment outcomes.
Purpose of the Study:
- To review and comparatively analyze in-vitro platforms for personalized immunotherapy drug screening.
- To evaluate the suitability, high-throughput capacity, and clinical translatability of different assays.
- To discuss end-point analysis strategies for optimizing experimental design in immunotherapy efficacy prediction.
Main Methods:
- Comparative analysis of various in-vitro assays (2D models, organoid co-cultures, cancer-on-a-chip).
- Evaluation of assay construction strategies, advantages, and limitations.
- Discussion of image-based assays and their potential and challenges.
Main Results:
- In-vitro platforms offer diverse insights into personalized immunotherapy efficacy.
- Image-based assays excel in capturing cellular details but face challenges like background noise and lengthy experiments.
- Significant improvements and validation are needed for clinical application.
Conclusions:
- Optimizing in-vitro assays is critical for advancing personalized immunotherapy.
- Further research and clinical trials are essential to validate and refine these platforms for real-world use.
- Standardized end-point analysis will enhance the predictive power of these assays.
Related Concept Videos
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...